Latest Articles
- Vitamin D: A metabolic bone disease perspective
When checking levels, clinicians should keep in mind that vitamin D levels fluctuate by season and time of day, and that different laboratories may use different assays that yield different results.
- What are the treatment options for myasthenia gravis if first-line agents fail?
From 5% to 20% of patients may have a suboptimal response or prohibitive adverse effects over a period of a few weeks to 3 months.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
- Oral leukoplakia and oral cancer
A 53-year-old male who had smoked for 36 years was referred by his dentist for worsening vitiligo diagnosed as leukoplakia 3 years earlier.
- Myasthenia gravis: An update for internists
Recognizing the spectrum of the disease in patients’ complaints enhances our clinical reasoning skills when faced with the extremely commonly expressed symptom of “fatigue.”
- Myasthenia gravis: Frequently asked questions
Who is at risk? Which tests should be ordered? How does the disease course affect management decisions? What instructions should you give patients? And other questions.
- Statins may increase diabetes, but benefit still outweighs risk
The weight of the evidence suggests that statin use is associated with an increased risk of new-onset diabetes mellitus, but the magnitude of the effect has varied across studies.
- Which patients hospitalized with alcohol withdrawal syndrome should receive high-dose parenteral thiamine?
The authors briefly outline risk factors for Wernicke encephalopathy and when high-dose parenteral thiamine is indicated.
- Making best use of bone turnover markers to monitor oral bisphosphonate therapy
Clinical applications of bone turnover markers can include determining when to start or end a bisphosphonate “holiday” and measuring treatment response.